Universal (UVV) Q2 2027 earnings summary

Executive summary

• Delayed tobacco shipments amid an oversupply cycle and ongoing Ingredients pressures weakened Q2 and H1 FY27 results; shipments are expected to be heavily weighted to H2.

• Tobacco customer commitments remained aligned with full-year sales plans; uncommitted inventory was 19% at September 30 and within the target range.

• Ingredients transformation is continuing through FY28, with a focus on commercial execution, facility utilization, and operating efficiency.

Financial highlights

• Q2 revenue was $621.8M vs. $754.2M; operating income was $42.6M vs. $67.6M, and net income attributable was $12.6M vs. $34.2M.

• H1 revenue was $1,145.6M vs. $1,347.9M; operating income was $44.9M vs. $101.5M, and net income attributable was $7.6M vs. $42.7M.

• Diluted EPS was $0.50 in Q2 and $0.30 in H1, vs. $1.36 and $1.70; adjusted diluted EPS was $0.39 and $0.19, vs. $1.36 and $1.74.

• Gross margin was 17.3% in Q2 vs. 18.5%, and 16.6% in H1 vs. 18.8%.

Outlook and guidance

• Tobacco shipments and results are expected to skew to H2, consistent with seasonality; customer commitments support confidence in the full-year sales plan, and uncommitted inventories are expected to decline.

• Emerging customer interest in additional tobacco volumes, partly linked to El Niño concerns, may provide upside; timing and volume depend on customer decisions and crop conditions.

• FY27 SG&A guidance remained $300M-$310M; expected capital spending was $60M-$70M over the next 12 months.

• Ingredients improvement initiatives will continue through FY28; management said the timing and pace of financial benefits remain difficult to pinpoint.